Literature DB >> 11031094

Gene therapies that enhance hippocampal neuron survival after an excitotoxic insult are not equivalent in their ability to maintain synaptic transmission.

T C Dumas1, J R McLaughlin, D Y Ho, M S Lawrence, R M Sapolsky.   

Abstract

Research shows that overexpression of cytoprotective genes can spare neurons from necrotic death, but few studies have addressed the functional status of surviving neurons. Overexpression of a brain glucose transporter, Glut-1, or the anti-apoptotic protein, Bcl-2, in rats decreases the size of hippocampal lesions produced by kainic acid (KA) treatment. In animals in which KA-induced lesions are reduced to similar extents by Glut-1 or Bcl-2 overexpression, spatial learning is spared by Glut-1, but not Bcl-2. We postulated that Glut-1 and Bcl-2 act differently to protect hippocampal function and investigated the effects of vector overexpression on synaptic physiology after KA treatment. Three days after KA and vector delivery to the dentate gyrus, mossy fiber-CA3 (MF-CA3) population excitatory postsynaptic potentials (EPSPs) were recorded in vitro. In addition to producing a lesion in area CA3, KA treatment reduced baseline MF-CA3 synaptic strength, posttetanic potentiation (PTP), and long-term potentiation (LTP). A similar reduction in the KA-induced lesion was produced by overexpression of Glut-1 or Bcl-2. Glut-1, but not Bcl-2, attenuated the impairments in synaptic strength and PTP. Overexpression of Glut-1 or Bcl-2 preserved LTP after KA treatment. Results indicate greater protection of MF-CA3 synaptic transmission with overexpression of Glut-1 compared to Bcl-2 and suggest that not all neuroprotective gene therapy techniques are equivalent in their ability to spare function. Copyright 2000 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11031094     DOI: 10.1006/exnr.2000.7500

Source DB:  PubMed          Journal:  Exp Neurol        ISSN: 0014-4886            Impact factor:   5.330


  7 in total

1.  Sparing of neuronal function postseizure with gene therapy.

Authors:  J McLaughlin; B Roozendaal; T Dumas; A Gupta; O Ajilore; J Hsieh; D Ho; M Lawrence; J L McGaugh; R Sapolsky
Journal:  Proc Natl Acad Sci U S A       Date:  2000-11-07       Impact factor: 11.205

2.  Microglial Toll-like receptor 2 contributes to kainic acid-induced glial activation and hippocampal neuronal cell death.

Authors:  Jinpyo Hong; Ik-Hyun Cho; Kyung Il Kwak; Eun Cheng Suh; Jinsoo Seo; Hyun Jung Min; Se-Young Choi; Chong-Hyun Kim; Seung Hwa Park; Eun-Kyeong Jo; Soojin Lee; Kyung Eun Lee; Sung Joong Lee
Journal:  J Biol Chem       Date:  2010-10-05       Impact factor: 5.157

3.  The growth compromised HSV-2 mutant DeltaRR prevents kainic acid-induced apoptosis and loss of function in organotypic hippocampal cultures.

Authors:  Michael D Gober; Jennifer M Laing; Scott M Thompson; Laure Aurelian
Journal:  Brain Res       Date:  2006-10-03       Impact factor: 3.252

4.  Protective effect of propofol preconditioning on ischemia-reperfusion injury in human hepatocyte.

Authors:  Yuzhu Zhang; Zhenzhen Chen; Nianhai Feng; Junxia Tang; Xingbo Zhao; Chengxiao Liu; Hongyu Xu; Mengyuan Zhang
Journal:  J Thorac Dis       Date:  2017-03       Impact factor: 2.895

5.  Anti-glucocorticoid gene therapy reverses the impairing effects of elevated corticosterone on spatial memory, hippocampal neuronal excitability, and synaptic plasticity.

Authors:  Theodore C Dumas; Todd Gillette; Deveroux Ferguson; Kelly Hamilton; Robert M Sapolsky
Journal:  J Neurosci       Date:  2010-02-03       Impact factor: 6.167

6.  Neonatal exposure to antiepileptic drugs disrupts striatal synaptic development.

Authors:  Patrick A Forcelli; Megan J Janssen; Stefano Vicini; Karen Gale
Journal:  Ann Neurol       Date:  2012-05-11       Impact factor: 10.422

7.  DeltaRR vaccination protects from KA-induced seizures and neuronal loss through ICP10PK-mediated modulation of the neuronal-microglial axis.

Authors:  Jennifer M Laing; Laure Aurelian
Journal:  Genet Vaccines Ther       Date:  2008-01-07
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.